China Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Description

List of Tables

GlobalData's "China Oncology Market Outlook to 2033" is a comprehensive databook report, covering key market data on the China Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The China Oncology Market report provides key information and data on -

Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2024 company share data for Oncology Market.
Global corporate-level profiles of key companies operating within the China Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

China Oncology is segmented as follows -

Colorectal Cancer Screening Tests
EGFR Tests
KRAS Tests
HER2 Tests
BRCA Tests
ALK Tests
BRAF Tests
BCR-ABL Tests
PD-L1 Tests

Reasons to Buy

The China Oncology Market report helps you to develop -

Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Product Code: GDME25617CCDB

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 What Is This Report About?
2.2 Oncology Market Segmentation
2.3 Definitions of Markets Covered in the Report

3 Oncology Market, China

3.1 Oncology Market, China, Revenue ($m), 2018-2033
- 3.1.1 ALK Tests Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.2 BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.3 BRAF Tests Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.4 BRCA Tests Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.5 Colorectal Cancer Screening Tests Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.6 EGFR Tests Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.7 HER2 Tests Market, China, Revenue ($m), by Segment, 2018-2033
- 3.1.8 KRAS Tests Market, China, Revenue ($m), by Segment, 2018-2033
3.2 Oncology Market, China, Volume (Units), 2018-2033
- 3.2.1 ALK Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.2 BCR-ABL Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.3 BRAF Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.4 BRCA Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.5 Colorectal Cancer Screening Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.6 EGFR Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.7 HER2 Tests Market, China, Volume (Units), by Segment, 2018-2033
- 3.2.8 KRAS Tests Market, China, Volume (Units), by Segment, 2018-2033
3.3 Oncology Market, China, Average Price ($) , 2018-2033
3.4 Oncology Market, China, Company Share by Revenue ($m), 2024

4 Overview of Key Companies in China, Oncology Market

4.1 F. Hoffmann-La Roche Ltd
- 4.1.1 Company Overview
4.2 BioGenex Laboratories Inc
- 4.2.1 Company Overview
4.3 Amoy Diagnostics Co Ltd
- 4.3.1 Company Overview
4.4 Abbott Laboratories
- 4.4.1 Company Overview
4.5 Danaher Corp
- 4.5.1 Company Overview
4.6 Eiken Chemical Co Ltd
- 4.6.1 Company Overview
4.7 Agilent Technologies Inc
- 4.7.1 Company Overview
4.8 Hemosure Inc
- 4.8.1 Company Overview
4.9 Alfresa Pharma Corp
- 4.9.1 Company Overview
4.10 SENTINEL CH SpA
- 4.10.1 Company Overview

5 Oncology Market Pipeline Products

6 Financial Deals Landscape

6.1 Equity Offerings
- 6.1.1 Pheton Holdings (Beijing Feitian Zhaoye Technology) Raises USD9 Million in Initial Public Offering (IPO) of Shares
- 6.1.2 Elpiscience Biopharma to Raise Funds through Initial Public Offering (IPO) of Shares
6.2 Partnerships
- 6.2.1 Guangzhou Concord Cancer Center Enters into Licensing Agreement for Proton Therapy Equipment
6.3 Venture Financing
- 6.3.1 Suzhou Linaxin Biotechnology (Linaxin) Secures Series A Funding
- 6.3.2 Shanghai Tongshu Biological Technology (Changzhou Tongshu Biological Technology, Tongshu Gene, Tung Tree Gene) Raises Approximately USD14.15 Million in Series D Financing
- 6.3.3 Jiangsu Xunyuan Biotech Raises More than USD13.75 Million in Venture Financing
- 6.3.4 Shenyang Neusoft Zhirui Radiotherapy Technology (Neusoft Zhirui) Raises Approximately USD13.77 Million in Series C Financing

7 Recent Developments

7.1 Other Significant Developments
- 7.1.1 Mar 03, 2025: TruScreen - Key Markets Update and Revenue Guidance
- 7.1.2 Sep 12, 2024: BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
7.2 Product News
- 7.2.1 May 29, 2025: Concord Healthcare Announces Official Release of the Proton Therapy Large Model
- 7.2.2 Apr 27, 2025: The Group's Early Detection Product for Urinary System Tumors Achieves Its First Commercial Prescription in Mainland China
- 7.2.3 Feb 16, 2025: HKU Team Develops AI-Driven Tool to Accelerate Cancer Diagnosis
- 7.2.4 Feb 14, 2025: New Patent Approval in China Strengthens the AroCell Patent Portfolio
- 7.2.5 Jan 15, 2025: CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology
- 7.2.6 Nov 11, 2024: Report Published by Research Journal, Germany's Springer Concluded that TruScreen Cervical Cancer Screening Results were Comparable and Better than conventional LBC
- 7.2.7 Sep 20, 2024: Researchers Use Cholesterol-Enriched Exosomes to Improve Sirna Delivery
- 7.2.8 Sep 16, 2024: Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
- 7.2.9 Aug 23, 2024: Breakthroughs in Prostate Cancer: New Insights into Biomarkers and Probes
7.3 Strategy And Business Planning
- 7.3.1 Sep 12, 2024: BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
- 7.3.2 Jul 11, 2024: MGI Announces Collaboration With Predica Diagnostics
- 7.3.3 Jun 28, 2024: Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China

8 Appendix

8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer

Product Code: GDME25617CCDB

List of Table

List of Tables

Table 1: Oncology Market, China, Revenue ($m), USD Constant, 2018-2033
Table 2: ALK Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 3: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), USD Constant, 2018-2033
Table 4: BRAF Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 5: BRCA Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 6: Colorectal Cancer Screening Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 7: EGFR Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 8: HER2 Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 9: KRAS Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Table 10: Oncology Market, China, Volume (Units), 2018-2033
Table 11: ALK Tests Market, China, Volume (Units), 2018-2033
Table 12: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Volume (Units), 2018-2033
Table 13: BRAF Tests Market, China, Volume (Units), 2018-2033
Table 14: BRCA Tests Market, China, Volume (Units), 2018-2033
Table 15: Colorectal Cancer Screening Tests Market, China, Volume (Units), 2018-2033
Table 16: EGFR Tests Market, China, Volume (Units), 2018-2033
Table 17: HER2 Tests Market, China, Volume (Units), 2018-2033
Table 18: KRAS Tests Market, China, Volume (Units), 2018-2033
Table 19: Oncology Market, China, Average Price ($), 2018-2033
Table 19: Oncology Market, China, Company Share by Revenue ($m), 2024
Table 20: Oncology Market Pipeline Products
Table 21: Pheton Holdings (Beijing Feitian Zhaoye Technology) Raises USD9 Million in Initial Public Offering (IPO) of Shares
Table 22: Elpiscience Biopharma to Raise Funds through Initial Public Offering (IPO) of Shares
Table 23: Guangzhou Concord Cancer Center Enters into Licensing Agreement for Proton Therapy Equipment
Table 24: Suzhou Linaxin Biotechnology (Linaxin) Secures Series A Funding
Table 25: Shanghai Tongshu Biological Technology (Changzhou Tongshu Biological Technology, Tongshu Gene, Tung Tree Gene) Raises Approximately USD14.15 Million in Series D Financing
Table 26: Jiangsu Xunyuan Biotech Raises More than USD13.75 Million in Venture Financing
Table 27: Shenyang Neusoft Zhirui Radiotherapy Technology (Neusoft Zhirui) Raises Approximately USD13.77 Million in Series C Financing
Table 28: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

List of Figure

List of Figures

Figure 1: Oncology Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 2: ALK Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 3: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 4: BRAF Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 5: BRCA Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 6: Colorectal Cancer Screening Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 7: EGFR Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 8: HER2 Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 9: KRAS Tests Market, China, Revenue ($m), USD Constant, 2018-2033
Figure 10: Oncology Market, China, Volume (Units), 2018-2033
Figure 11: ALK Tests Market, China, Volume (Units), 2018-2033
Figure 12: BCR-ABL Tests Market, China, Volume (Units), 2018-2033
Figure 13: BRAF Tests Market, China, Volume (Units), 2018-2033
Figure 14: BRCA Tests Market, China, Volume (Units), 2018-2033
Figure 15: Colorectal Cancer Screening Tests Market, China, Volume (Units), 2018-2033
Figure 16: EGFR Tests Market, China, Volume (Units), 2018-2033
Figure 17: HER2 Tests Market, China, Volume (Units), 2018-2033
Figure 18: KRAS Tests Market, China, Volume (Units), 2018-2033
Figure 19: Oncology Market, China, Company Share (%), 2024